Guideline‑Recognized Dizziness and Sedation Risks of Scopolamine Transdermal Patches

Otology Guidelines on Anticholinergic Adverse Effects

• The 2020 American Academy of Otolaryngology‑Head and Neck Surgery (AAO‑HNS) clinical practice guideline for Ménière’s disease identifies scopolamine and other anticholinergics as agents that can cause sedation, blurred vision, dry mouth, pupil dilation, urinary retention, and related dizziness‑type side effects in patients. 1, 2

Cardiovascular/Stroke Guidelines on Neurological Assessment

• The 2023 American Heart Association/American Stroke Association (AHA/ASA) guideline cautions that anticholinergic drugs such as scopolamine may impair the neurological examination by producing confusion or sedation, which can present as dizziness in patients undergoing stroke evaluation. 3